OrbiMed's $39 Million Sale: A Strategic Exit, Not a Bearish Signal, for Enliven Therapeutics

Related Articles

Allbirds' $39 Million Sale: A Cautionary Tale for the IPO Class of 2021

3 months ago

What Does a $1.1 Million CEO Stock Sale Signal for NextNav Investors

4 months ago

Is Enliven Therapeutics (ELVN) a Buy After Its Upsized Offering and Positive Clinical Data

3 weeks ago

What Does Sarepta Therapeutics' Director Share Sale Signal to Investors

3 months ago

Category

You may also like

Stock News•2 days ago

Abivax nears $11 billion valuation after fundraising eases M&A pressure

Abivax SA raised $800M in an expanded share sale after strong demand, valuing the firm at ~$11B and easing near-term M&A pressure.

ABVX

Share

Stock News•6 days ago

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

OrbiMed sold 860,123 Enliven Therapeutics shares (~$39M at $45.36 each) on June 22, 2026, reducing indirect holdings by 11.6% after a 130% rally.

ELVN

Share

Stock News•1 months ago

This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced

Biotech firms are increasingly licensing programs from a single geographic region, marking a shift in industry strategy. This concentration of external development creates a new, unprecedented risk pr...

SMMT

Share

Stock News•1 months ago

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Orchestra BioMed received a $20M payment from Medtronic, fulfilling a previously disclosed funding commitment. The capital supports the completion of the BACKBEAT Global Pivotal Trial, which evaluates...

MDT

Share